Salmon DNA / Polynucleotide Treatment

“Salmon DNA treatment” is one of those names that is easy to remember and clinically difficult to define.

The phrase suggests that DNA itself is being injected into the face as though genetic material were somehow rewriting the skin into a younger version of itself.

That is not an accurate way to understand the treatment.

Products in this category generally contain purified DNA-derived polymers known as polynucleotides or related polydeoxyribonucleotide preparations. They are commonly derived from salmonid fish sources because highly purified DNA fragments can be obtained and processed for medical use.

But even here the terminology is not clean.

Polynucleotide, PN and PDRN are sometimes used interchangeably in aesthetic marketing even though they can refer to DNA fragments with different chain lengths, molecular weights and physicochemical behaviour.

Different commercial products also use different concentrations, purification systems and formulations.

So I do not think “salmon DNA” should become the treatment diagnosis.

The important questions are: which DNA-derived material is actually being injected, what evidence exists for that formulation, and what aspect of the skin are we asking it to improve?

Salmon is the source; it is not the mechanism

The source of a biomaterial matters for manufacturing and purification.

It does not explain the clinical effect by itself.

Calling a product salmon DNA can make the treatment sound unusually natural or biologically compatible. But clinical behaviour depends on the purified molecular product that remains after extraction, deproteinisation, sterilisation and formulation.

The relevant material is not a piece of salmon tissue being placed into the skin.

It is a processed DNA-derived polymer.

“Salmon DNA” tells me where the raw biological material came from.

It does not tell me the molecular weight, concentration, clinical evidence or correct indication of the final injectable.

I would rather discuss those variables because they are the ones that influence treatment.

Polynucleotides and PDRN are related but should not automatically be treated as identical

This is an area where both commercial language and scientific literature have historically been inconsistent.

PN and PDRN are DNA-derived biopolymers composed of nucleotide chains.

More recent reviews increasingly distinguish them according to polymer length and molecular weight. Polynucleotides generally refer to longer-chain, higher-molecular-weight material, while PDRN refers to comparatively shorter deoxyribonucleotide fragments.

That difference can change physical behaviour.

Longer PN chains can have greater viscoelastic properties and may influence extracellular matrix interactions differently from shorter PDRN fragments.

PDRN has also been extensively investigated in relation to adenosine A2A-receptor signalling and nucleotide salvage pathways, particularly in wound-healing research.

The important point is not to turn this into molecular trivia.

It is to recognise that evidence obtained with one molecular preparation should not automatically be transferred to every injectable sold under the broader “salmon DNA” label.

The treatment is not gene therapy

This misconception deserves a direct answer.

Injecting purified polynucleotides into the dermis does not rewrite the patient’s genetic code.

It does not insert salmon genes into human cells.

It is not designed to permanently alter DNA expression by integrating foreign genetic material into the patient’s genome.

These products are being investigated and used as biomaterials with proposed effects on tissue hydration, extracellular matrix biology, inflammation and repair signalling.

The word DNA refers to the molecular origin of the polymer.

It should not be allowed to create science-fiction expectations about rejuvenation.

The most coherent treatment target is skin quality

I position polynucleotide treatment primarily as a skin-quality intervention.

The patient may have thin, crepey or dehydrated-looking skin. Fine superficial lines may have become more visible. The tissue may look less elastic or less resilient than before.

Those concerns are conceptually closer to what current PN research has investigated.

I would not place a significant jowl, major cheek-volume deficiency or substantial upper-eyelid skin excess in the same treatment category.

Those are structural problems.

A skin-quality injectable can improve the environment of the skin without becoming structural filler or surgery.

This boundary makes the treatment more useful because it protects it from being asked to do everything.

Hydration can improve even when the product is not primarily a hyaluronic-acid skin booster

Patients often compare PN directly with hyaluronic-acid skin boosters.

The categories overlap in desired outcome because both may be used when improved skin hydration and texture are wanted.

The materials are different.

Hyaluronic acid has strong water-binding properties and can improve tissue hydration through that physical behaviour.

Long-chain polynucleotides have their own hydrophilic and viscoelastic characteristics and are proposed to influence the tissue environment through additional biological pathways.

This does not mean PN is automatically “more regenerative” or clinically superior.

Head-to-head evidence remains limited.

The choice should come from what formulation is being considered, the available evidence and the patient’s skin rather than from a hierarchy in which every newer injectable must outperform the previous category.

The fibroblast story is plausible, but plausibility is not the same thing as a guaranteed clinical result

Polynucleotide products are commonly described as stimulating fibroblasts, increasing collagen and repairing the extracellular matrix.

There is experimental rationale for effects on fibroblast activity and tissue repair, and clinical studies report improvements in parameters such as elasticity, wrinkles and texture.

But clinical aesthetic medicine requires another step.

It is not enough to show that a pathway associated with collagen can be influenced.

We need to know whether the visible improvement is meaningful, reproducible and sufficiently durable in real patients.

A molecule can have a credible regenerative mechanism without every regenerative marketing claim becoming clinically proven.

This is why I am comfortable describing PN as promising while still maintaining limits around what has actually been established.

The current evidence is positive enough to take seriously and limited enough to remain cautious

The recent evidence base has grown.

A systematic review of aesthetic PN use identified improvements in wrinkles, texture and elasticity across several studies, with generally mild and transient adverse effects.

But the same review found only nine qualifying studies and 219 patients, and study quality was mainly low to moderate.

A newer systematic review focused on randomised trials of PN and PDRN across rejuvenation, scar prevention and wound healing still identified only seven trials involving 183 participants.

This is important.

The treatment is no longer supported only by anecdotes or laboratory theory.

At the same time, it does not yet have the depth of evidence that would justify universal protocols or broad claims of proven age reversal.

Both facts can be true simultaneously.

Periocular skin is an attractive indication precisely because it is difficult to treat with volume

The skin around the eyes is thin.

Fine crepiness and texture change can become visible even when there is no major structural hollow.

This creates a therapeutic gap.

Adding filler where volume is not genuinely deficient can produce puffiness or heaviness. Strong resurfacing may involve more downtime than the patient wants.

A skin-quality injectable can therefore be conceptually attractive in selected periocular patients.

But I keep the endpoint modest.

Polynucleotides do not remove lower-eyelid fat bags. They do not correct a true tear trough through structural volume replacement. They do not perform blepharoplasty.

The aim is improved skin quality around the eye, not reconstruction of every component of periorbital ageing.

Thin under-eye skin and a tear trough should not be treated as the same diagnosis

A patient may have fine lower-eyelid skin and no significant volume deficit.

Another may have an anatomical tear trough casting a deep shadow.

A third may have both.

PN treatment may be reasonable when skin quality is the dominant concern.

Structural filler may be more relevant when a clean volume deficit is responsible for the shadow.

In other patients, prominent bags or edema make additional injectable treatment less attractive altogether.

One of the advantages of keeping PN in the skin-quality category is that the treatment decision becomes clearer.

I do not want every problem around the eye to become an excuse for another injectable.

PN treatment is not structural filler even if temporary papules make the skin look fuller

After superficial injections, small raised papules and swelling can be visible.

This temporarily makes the treated skin appear fuller.

That early volume is not the endpoint.

It reflects product placement and tissue response during recovery.

Polynucleotide gels can have physical viscoelastic properties, particularly with higher-molecular-weight formulations, but I still do not use them conceptually as a substitute for cheek, chin or temple filler when actual structural volume is missing.

Using a skin-quality treatment repeatedly in an attempt to create structural projection would blur the treatment categories again.

Skin texture improvement should not be translated into scar removal

PN and PDRN have attracted interest in scar treatment and wound healing because tissue repair is central to their proposed biology.

There are encouraging clinical studies.

But a scar still has architecture.

A tethered acne scar is mechanically anchored. A hypertrophic scar contains excess fibrotic tissue. A keloid has an abnormal growth tendency. A fine postoperative scar presents another problem again.

A bioregenerative injectable cannot be assumed to solve all of these simply because collagen is involved in each one.

I would consider PN or PDRN as a potential adjunct in selected scar contexts when evidence supports it.

I would not replace scar classification with the word regeneration.

PN and PDRN may have interesting roles after procedures, but adjunctive treatment should remain adjunctive

There is increasing interest in PDRN and related DNA-derived treatments after laser resurfacing, microneedling and other procedures.

The proposed objective is to support re-epithelialisation, reduce inflammatory recovery or influence subsequent remodelling.

Recent reviews describe encouraging human data for several post-procedure outcomes.

That does not mean every laser or microneedling session should automatically be followed by PDRN.

The primary procedure is still creating the main injury and much of the resulting remodelling.

If an adjunct improves recovery, that additional benefit should be demonstrated and judged separately.

I do not want the success of a good laser treatment retrospectively converted into proof that every product applied afterwards was necessary.

“Biostimulation” should remain different from “regeneration”

These words are often used interchangeably.

I prefer more restraint.

If a treatment influences fibroblast activity, extracellular matrix organisation or repair pathways, describing it as biostimulatory may be reasonable.

Regeneration is a much larger word.

It can imply restoration of tissue toward a previous biological state.

Current PN evidence does not justify telling patients that aged skin has been regenerated back to youth.

Improved hydration, texture, elasticity or fine wrinkling can be excellent results without requiring that claim.

More concentrated product is not automatically a more effective treatment

Commercial PN products vary in concentration and molecular characteristics.

That can influence viscosity, tissue behaviour and intended treatment plane.

It is tempting to compare products by the largest concentration printed on the package.

But concentration alone does not tell me clinical effectiveness.

A product used for thin periocular skin may have a different formulation objective from one intended for broader facial treatment.

The useful question is whether the product characteristics match the tissue and indication.

A stronger number does not replace that match.

Fish allergy deserves a more precise discussion than the treatment name allows

Because PN products are often derived from salmonid sources, patients with fish allergy understandably ask whether they are at risk.

Highly purified products undergo processing intended to remove proteins and peptides that would be more likely to provoke classical protein-mediated allergic reactions.

This may reduce immunogenicity substantially.

But the correct approach is still product-specific.

I want to know the manufacturer, purification process, contraindications and labelling of the exact injectable being used rather than provide a blanket statement that “salmon DNA cannot cause allergy”.

Purity is a manufacturing question, not a slogan.

Product traceability matters because “polynucleotide” does not identify one regulated formulation

Commercial popularity creates another problem.

Once a category becomes fashionable, the number of products using similar terminology increases.

I want the exact product to be traceable.

Its manufacturer, intended use, storage, sterility, concentration and regulatory status should be identifiable.

A product sold online with attractive PN branding should not be assumed equivalent to a medically manufactured injectable used in published clinical studies.

Evidence belongs to characterised products and interventions.

It does not automatically transfer to every syringe using the same category word.

Regulatory status and clinical evidence are different questions

A product can legally enter a market through a particular regulatory pathway and still have a relatively young clinical evidence base.

Another product can have interesting published data without being authorised for every indication in every country.

I keep those questions separate.

Is the product appropriately regulated for the use being proposed?

What clinical evidence supports that use?

How strong is that evidence?

Those are three different questions.

Market availability does not convert uncertainty into proof.

The injection technique is part of the treatment

PN products can be delivered using small intradermal papules, linear techniques or other patterns depending on formulation and anatomical area.

The treatment plane matters.

A superficial periocular skin-quality treatment and a deeper facial injection are not identical procedures simply because both use PN.

Bruising, swelling and papules can vary according to technique.

The anatomical risk also changes by region.

I therefore do not regard a prefilled syringe as a complete treatment protocol.

The material and the way it is delivered have to be considered together.

Temporary papules are expected in many protocols, but recovery should not be trivialised

Small bumps at injection sites are common when PN is delivered intradermally.

They usually settle as the product disperses and tissue swelling resolves.

Bruising, tenderness, redness and temporary edema can also occur.

For a patient treating the lower eyelids, even small swelling may be socially noticeable.

I therefore do not use the phrase “zero downtime” simply because the patient does not need to stop working medically.

Social downtime and medical downtime are different.

The patient should know what they may actually see in the mirror.

Repeated sessions need to be justified by a product-specific protocol and real response

Many PN treatment programmes use an initial series followed by maintenance.

This is common in the published literature and in expert consensus.

But there is not yet one universally established protocol across all products, anatomical regions and indications.

This is exactly what recent systematic reviews identify as a weakness in the evidence base.

I therefore treat protocol as guidance rather than dogma.

If the skin is improving and the treatment course has a reasonable evidence basis, continuing can make sense.

If there has been little meaningful change, automatically completing more injections because PN is “regenerative” does not make the treatment more scientific.

The result needs time because we are not only looking for post-injection swelling

Some early changes may be visible relatively soon, particularly hydration-related changes.

The biological effects proposed around extracellular matrix remodelling and tissue quality are expected to evolve more gradually.

This makes immediate before-and-after photography particularly unreliable.

Freshly injected skin is swollen.

Small wrinkles can temporarily appear softer simply because fluid has been introduced into the tissue.

I want the result assessed after that early noise has resolved.

If the treatment is genuinely improving skin quality, the benefit should still be visible when the injection reaction is no longer doing the work.

Maintenance should not become endless biostimulation

There is a tendency to assume that because ageing continues, biostimulatory treatment should continue indefinitely.

I do not think that follows automatically.

If the patient has obtained useful improvement and later notices that the original skin-quality concern has returned, maintenance can be reasonable.

If the skin remains satisfactory, another treatment is not necessary simply because a certain interval has passed.

If a new structural ageing problem has developed, repeating PN may also be the wrong response.

Maintenance should follow what the tissue needs now.

It should not become a ritual intended to keep “regeneration switched on”.

What a good polynucleotide result means to me

I expect subtle improvement.

The skin may look better hydrated and more resilient. Fine crepey texture may soften. Selected superficial lines may become less distracting. The tissue may appear healthier without an obvious change in facial shape.

I do not expect a new cheekbone.

I do not expect a significant jowl to lift. I do not expect lower-eyelid bags to disappear. I do not expect a mature scar architecture to be erased by biological signalling alone.

The treatment is most convincing when the patient looks like they have better skin rather than more injectable product.

When polynucleotide treatment makes sense to me

I am most comfortable recommending PN when skin quality itself is the target and the product being used is clearly characterised, appropriately regulated and supported by a reasonable evidence base.

Thin, crepey or dehydrated-looking skin and selected periocular quality concerns are coherent examples.

I become more cautious when the treatment is being sold as an alternative to structural filler, surgery or established scar treatment, when the product identity is vague, or when “salmon DNA” is being used to imply scientific certainty that the specific formulation has not earned.

Polynucleotides are an interesting and increasingly evidence-supported aesthetic category.

The evidence is also still developing.

I think the correct response to that combination is neither dismissal nor enthusiasm without limits.

It is to use the treatment where its current biology and evidence make sense — and allow the evidence to grow before the claims do.

Frequently asked questions

What is Salmon DNA treatment?

It is a popular name for injectable treatments containing purified DNA-derived polymers, commonly polynucleotides or related PDRN preparations obtained from salmonid sources. The exact formulation varies between products.

Are polynucleotides and PDRN the same thing?

They are related DNA-derived biomaterials but are increasingly distinguished by polymer length and molecular weight. PN generally refers to longer-chain material, while PDRN contains shorter DNA fragments. The terms have historically been used inconsistently.

Does salmon DNA change my own DNA?

No. This is not gene therapy. The treatment does not integrate salmon genes into your genome or genetically reprogram your skin.

What do polynucleotides actually do?

They are being used and studied for skin hydration, texture, elasticity, fine wrinkling and tissue-repair applications. Proposed mechanisms involve extracellular matrix and repair signalling, but the strength of clinical evidence varies by product and indication.

Do polynucleotides stimulate collagen?

There is biological rationale and clinical evidence suggesting effects on fibroblast and extracellular-matrix behaviour, but I would not translate this into a promise of dramatic collagen rebuilding or structural lifting.

Are polynucleotides better than hyaluronic-acid skin boosters?

There is not enough high-quality head-to-head evidence to declare one category universally superior. They have different material properties and proposed mechanisms, and the choice should depend on the patient and the specific formulation.

Can polynucleotides treat under-eye hollows?

They can be useful for selected periocular skin-quality concerns, but they are not a direct substitute for structural tear-trough filler when genuine volume loss is the dominant problem.

Can they treat eye bags?

They do not remove prolapsed lower-eyelid fat or significant excess skin. Those are structural problems requiring a different assessment.

Can polynucleotides treat acne scars?

They are being investigated in scar and repair applications, but scar architecture still determines treatment. A tethered or deep acne scar generally requires a mechanism capable of correcting that structure.

How strong is the evidence?

Current systematic reviews describe promising improvements in wrinkles, texture, elasticity and other skin-quality outcomes, but the number of high-quality studies remains relatively small and protocols are not yet fully standardised.

Is treatment safe if I have a fish allergy?

Products are highly purified to reduce protein contamination, but suitability should be determined from the exact manufacturer’s formulation and contraindications rather than assuming every fish-derived PN product is identical.

How many sessions are required?

Protocols vary between products and anatomical areas. I prefer to use a product-specific evidence-based protocol with reassessment rather than one universal PN schedule.

How long does the result last?

Duration varies with formulation, skin condition and individual biology. Maintenance should be considered when a meaningful skin-quality concern returns rather than automatically according to a fixed calendar.

When would you recommend no polynucleotide treatment?

I would avoid it when the expected change requires structural volume or lifting, when the product cannot be clearly identified or appropriately regulated, or when the evidence for the specific claim being made is insufficient to justify an injectable treatment.